

BOOK BY 31 JULY
AND SAVE \$400

October 26-28 2020 | 9am-5pm EDT

Digital Event

www.tcr-therapies-summit.com

TCR-based therapies Summit

Digital Event



Supercharging T Cell Receptor Redirection

Weaponize your TCR therapy, acquire diverse target repertoires for comprehensive immune responses, overcome the hostile tumor microenvironment & ensure persistence *in vivo*

Expert Speakers Include:



Dolores Schendel
CEO
Medigene



David Berman
Head of Research &
Development
Immunocore



Paul Lammers
Chief Executive
Officer
**Triumvira
Immunologics**



Laurence Cooper
Chief Executive
Officer
Ziopharm Oncology



Chia Chen-Rogers
Senior Director,
Oncology Cell
Therapy New
Products
GSK

Proud to Partner With:



Join us at the forefront of TCR-based therapeutic development

TCR therapies are a promising route to supercharging our natural immune systems against cancer. Boasting large target repertoires, TCR-based therapies hold the power to tackle solid tumor heterogeneity.

The potential of TCR-based therapy is being realized as a record number of trials enter the clinic, bringing lifesaving therapy to patients who need it most.

At a critical time in TCR development, join us online at the **TCR-based Therapies Summit** to gain exclusive insights and network with industry leaders from **Triumvira**, **Fate Therapeutics**, **Immatics US** and many more.

Discuss never-before-seen data and learn from break-out companies including **Affinity Bio**.

This is the only industry focused, end-to-end, TCR-dedicated meeting to **optimize T cells**, enhance **target selection** and invade the hostile **tumor microenvironment** to accelerate best-in-class TCR-based therapies into the clinic.

Utilize this unique opportunity to pick the brains of the best. Join leaders from **TCR²**, **Ziopharm Oncology**, **3T Biosciences** and many more and learn how they are **expanding beyond HLA restriction**, assessing the toxicity of **enhanced affinity TCRs** and developing **optimal clinical approaches** for TCR-based therapies.

Stand on the cutting edge of target discovery, validation and T Cell optimization at the TCR-based Therapies Summit 2020.

Hear what industry leaders have to say

■ The TCR-based Therapies Summit will be a great forum to learn from and network with leading scientists and companies working to develop T cells as immunotherapy especially for solid tumors ■■

Laurence Cooper, Chief Executive Officer, **Ziopharm Oncology**

■ TCR based therapeutics and their targets are the next frontier in expanding the scope of cancer immunotherapy by providing access to currently undruggable oncogenic proteins ■■

David A. Scheinberg, Center for Experimental Therapeutics, **Memorial Sloan Kettering Cancer Center**


Navigate the safe & effective development of TCR-based therapies:




Arm your TCRs against the hostile tumor microenvironment with **Triumvira Immunologics**



Select & validate the best targets for your patient with **TScan Therapeutics & Anocca AB**



Unveil the Future of Manufacturing for Next-Generation TCRs with **Ziopharm Oncology & Fate Therapeutics**



Bring lifesaving therapy to patients around the globe by over-riding HLA restrictions with **T-Cure Bioscience**




Accelerate your therapies into the clinic with guidance from seasoned experts at **GSK**

Why now? *

A record number of trials entered the clinic in 2019 with 15 trials forecast to yield results in 2020. With an annual growth rate of 23.1%, this trend does not appear to be slowing, so this timely TCR-based therapy meeting is a unique opportunity to analyse and discuss progress as results emerge at a critical point in TCR development.

The large number of companies entering the TCR space is testament to progress in the field. With a combined effort to overcome HLA restrictions, there is a bright future for the delivery of TCR-based therapies to wider patient populations and cancer indications.

*Data acquired by Beacon Targeted Therapies



YOUR EXPERT SPEAKERS



Anthony Purcell
Professor Biochemistry
& Molecular Biology
**Monash Biomedicine
Discovery Institute**



Bob Valamehr
Chief Development
Officer
Fate Therapeutics



Blake Aftab
VP, Head of Preclinical
& Translational
Sciences
**Atara
Biotherapeutics, Inc**



Chia Chen-Rogers
Senior Director,
Oncology Cell
Therapy New
Products
GSK



Cheng Liu
Chief Executive
Officer
Eureka Therapeutics



David Berman
Head of Research &
Development
Immunocore



David Scheinberg
Chairman, Molecular
Pharmacology
**Memorial Sloan
Kettering Cancer
Center**



Dolores Schendel
Chief Executive
Officer
Medigene



Elisa Kieback
Chief Executive
Officer
T-knife



Erika Von Euw
Associate Director,
Translational
Research
**T-Cure Biosciences
Inc**



Gang Zeng
Chief Executive
Officer
**T-Cure Biosciences
Inc.**



Gavin MacBeath
Chief Scientific Officer
TScan Therapeutics



Hanspeter Gerber
Chief Scientific Officer
3T Biosciences



Hugh Salter
Chief Scientific Officer
Anocca AB



Laurence Cooper
Chief Executive
Officer
Ziopharm Oncology



Mark Omobono
Senior Associate
Scientist
Bluebird Bio



Michael Magee
Senior Scientist
Bluebird Bio



Paul Lammers
Chief Executive
Officer
**Triumvira
Immunologics**



Robert Hofmeister
Chief Scientific Officer
TCR²



Steffen Walter
Chief Scientific Officer
Immatics US

“A great opportunity to focus on the specifics of therapeutic TCR development, moving beyond CAR-T approaches”

Hugh Salter, Chief Scientific Officer, Anocca AB

WORKSHOP DAY MONDAY 26 OCTOBER 2020

Workshop A

9:00am – 12:00pm

Pre-clinical Development and Translation of TCR Therapy

Join this session to learn how researchers at Bluebird Bio & T-Cure Biosciences Inc. optimize and analyze T cell therapies to accelerate them into the clinic. Discuss the technical challenges and successes faced in effective safety assessment platform development and learn the tricks of translational efforts for TCR cell therapies.

- Moving into the clinic: a TCR toolkit
- Optimizing target selection & characterization
- Developing platforms for safety assessment
- Addressing translational challenges to ensure safety and therapeutic efficacy
- Leveraging TGF- β to invade the hostile tumor microenvironment

Workshop leaders:



Erika Von Euw
Associate Director,
Translational Research
T-Cure Biosciences Inc



Michael Magee
Senior Scientist
Bluebird Bio

Workshop B

1:00pm – 4:00pm

CMC & Manufacturing: Process Development of a Phase I TCR-T Product for Solid Tumor Indications

Join Bluebird Bio to optimize your process development for TCR-T products. Bring high-quality, functional TCR-T to patients in scaled doses through robust manufacturing platforms & discuss the best approaches to dose escalation and analytical studies.

- Interim results from ongoing TCR-based cellular therapy trials indicate that the doses required to induce an anti-tumor response are on the order of 10x those required for most CAR-T therapies.
- Optimizing the full therapeutic potential of TCR-based T cell therapies requires the development of robust manufacturing platforms that can overcome associated manufacturing challenges.
- Bluebird bio is developing a phase I transgenic TCR-T cell drug product manufacturing process intended for use in multiple solid tumor indications.

Workshop leader:



Mark Omobono
Senior Associate Scientist
Bluebird Bio

Mark worked in academic industry and biologics production for 6 years prior to bluebird bio. His working group, Cell Process Development, is responsible for design of all drug manufacturing processes across multiple commercial-, clinical- and development-stage programs at bluebird bio.

CONFERENCE DAY ONE

TUESDAY 27 OCTOBER 2020

8.00 Login & Morning Networking

8.45 Chair's Opening Remarks

Optimising TCR-based Therapies

Cheng Liu
Chief Executive
Officer
Eureka Therapeutics

9.00 Antibody Redirected TCR T-Cell Therapy for the Treatment of Solid Tumors

- Engineering ARTEMIS™ antibody TCR (AbTCR) T-cells
- Achieving high affinity and specificity by a TCR-mimic antibody
- Eliminating toxicity risks by engaging natural activation and regulatory pathways of gamma delta (γδ) TCR
- Enhancing tumor infiltration in the inhibitory microenvironment

Robert Hofmeister
Chief Scientific
Officer
TCR²

9.30 Engaging the full T cell receptor freed of HLA dependence

- Engineering a CAR-TCR hybrid to overcome the limitations of current immunotherapies
- Targeting multiple tumor antigens to elicit a comprehensive immune response
- Investigating pharmacodynamics to evaluate T Cell persistence and efficacy of the TruC platform



10.00 Morning Refreshments & Virtual Speed Networking

Grab a quick cup of coffee from the comfort of your own kitchen and jump straight into this exclusive virtual speed networking! This session is the ideal opportunity to meet face-to-face (albeit 2D faces) with many of the brightest minds working on TCR-based therapies and establish meaningful business relationships.

David Scheinberg
Chairman, Molecular
Pharmacology
**Memorial Sloan
Kettering Cancer
Center**

11.30 Drugging 'Undruggable' Cancer Targets with TCR Mimic Antibodies

- Targeting undruggable intracellular proteins using TCR mimic antibodies (TCRm)
- Utilizing TCRm in all platforms that traditional antibodies use (eg, enhanced IgG, T cell engagers, CAR T cells)
- Understanding the nature of the peptide/MHC complex and its potential regulation by drugs to realize the applications of TCRm
- Addressing new challenges posed by TCRm relating to potential off-target interactions

Steffen Walter
Chief Scientific
Officer
Immatics US

12.00 Allogeneic vs. Autologous Settings: A Quest for TCR-T Market Penetration

- Providing an overview of current success and challenges in autologous and allogeneic therapy
- Considering the merits and caveats of each approach
- Exploring the implications of HLA-dependence and target prevalence for TCR therapy & patient populations

12.30 Refreshment Break & Networking

Strategy to Expand Patient Populations

Gang Zeng
Chief Executive
Officer
**T-Cure Biosciences
Inc.**

1.30 Developing MHC Class II Restricted TCRs for Action in Solid Tumor Settings

- Describing the relative challenges and advantages of developing MHC class II TCRs
- Expanding to patient demographics in Asia
- Taking MHC class II TCRs into the clinic

2.00 Transcriptional Profiling & TCR Clonotypes to Gain Translational Insights for a Pre-Manufactured, Clinical Stage Allogeneic T-Cell Immunotherapy

Blake Aftab

VP, Head of Preclinical & Translational Sciences

Atara
Biotherapeutics, Inc

- Using 'omic-level analysis for translational characterization of allogeneic cell therapies derived from multiple donor sources
- Linking TCR clonotypes to relevant HLA's in relation to mechanism & diverse donor backgrounds
- Combining & leveraging complex datasets to best inform clinically relevant considerations for off-the-shelf TCR cell products

2.30 Panel Discussion: Advancing Beyond HLA 201 – Strategies for Delivery to a Wider Patient Population

- Identifying shared HLA across the population
- Comparison of techniques which are HLA-independent



David Berman

Head of Research & Development
Immunocore



Gang Zeng

Chief Executive Officer
T-Cure Biosciences Inc.



David Scheinberg

Chairman, Molecular Pharmacology
Memorial Sloan Kettering Cancer Center



Blake Aftab

VP, Head of Preclinical & Translational Sciences
Atara Biotherapeutics, Inc



3.15 Refreshment Break & Poster Session

Peruse digital posters and connect with authors to discuss their groundbreaking work!

Taking TCRs to the Clinic Safely

4.00 Presenting the Clinical validation of a Soluble Bispecific T cell Engager Platform

David Berman

Head of Research & Development
Immunocore

- Leveraging bi-specific biologics to combine TCRs with anti-CD3 effector functions for enhanced potency and specificity
- Using soluble ImmTAC molecules to mobilise multiple immune cell classes against cancer
- Inventing the ImmTAX 2.0 platform

4.30 Accelerating TCR Therapy into the Clinic

Dolores Schendel

CEO
Medigene

- Providing insights on the nuances TCR-based therapies to inform their acceleration into the clinic
- Anticipating challenges in the clinical development of next-generation TCR-based therapy
- Ensuring safety and efficacy of treatments in vivo
- Understanding the importance of comprehensive end-to-end immune monitoring from pre-clinical to clinical stages
- Glimpsing the powerful potential of TCR-based therapies with an overview of their success in the clinic

5.00 Chair's Closing Remarks

5.15 End of Day 1

■ Hanson Wade's CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area ■

Steffen Walter, Chief Scientific Officer, Immatics US

CONFERENCE DAY TWO

WEDNESDAY 28 OCTOBER 2020

8.00 Login & Morning Networking

9.15 Chair's Opening Remarks

Target Selection & Validation

Gavin MacBeath
Chief Scientific
Officer
TScan Therapeutics

9.30 Expanding TCR Therapy by Identifying New Targets and TCRs from Patient TILs

- Harnessing genome-wide, high-throughput screening to discover the natural targets of productive anti-tumor TCRs
- Developing genome-wide safety screening to identify all potential off-target interactions of therapeutic TCRs
- Rapid matching of TCRs and targets to address both shared antigens and private neoantigens

Hugh Salter
Chief Scientific Officer
Anocca AB

10.00 Functional Optimization and Characterization of TCRs Using Engineered Cell-Based Tools

- High-content and systematic diversification of candidate TCR chains
- Engineering human cell-based arrays for functional TCR selection
- Engineering human APC for systematic antigen presentation for standardised TCR safety profiling

10.30 Morning Refreshments & Networking

Hanspeter Gerber
Chief Scientific
Officer
3T Biosciences

11.30 Identification of Novel Shared Targets in Solid Tumors

- Comprehensively profiling peptide MHCs bound by TCRs using yeast display technology
- Profiling peptide MHCs of clinical TCRs: an opportunity to improve safety whilst maintaining anti-tumor activity
- Selecting lead TCRs using bioinformatics, yeast display & in vitro assays to measure TCR activity & specificity

Anthony Purcell
Professor
Biochemistry &
Molecular Biology
**Monash Biomedicine
Discovery Institute**

12.00 Developing Novel Tools for Selection & Prediction of Targets for Immunotherapy & Beyond

- Reviewing existing bioinformatics approaches and their limitations
- Developing molecular techniques to verify and predict neo epitopes on tumor biopsies
- Describing a novel 'Peptide-PCR' technique to amplify neoantigen signals from cancer biopsy and the application of this technology to infectious disease and autoimmune settings

Elisa Kieback
CEO
T-knife

12.30 Revealing a Humanized TCR Mouse Platform for High Affinity TCR Discovery

- Demonstrating that TCRs of higher affinity & specificity can be generated in humanized mice expressing a fully human diverse TCR repertoire
- Establishing proof-of-concept for the HuTCR mouse platform for >90 targets
- Showing that TCR combination approaches yield higher therapeutic benefit and increased T cell expansion in mice

1.00 Refreshment Break

Next-Generation TCR Development

Paul Lammers
Chief Executive
Officer
Triumvira
Immunologics

2.00 Opportunities in Solid Tumors

- Utilising TACs to guide T-Cells into tumors
- Demonstrating T-Cell persistence in mouse models of ALL
- Discussion of the clinical success of TCRs in the clinic

Laurence Cooper
Chief Executive
Officer
Ziopharm Oncology

2.30 Next-Generation Genetic Modification of T-Cells Using Non-Viral Therapy

- Targeting multiple antigens for a comprehensive immune response
- Using non-viral therapy to leverage neoantigen targets for personalised cell therapy

3.00 Afternoon Refreshments & Networking

Future Directions for TCR-T Products

Bob Valamehr
Chief Development
Officer
Fate Therapeutics

4.00 Creating the Perfect Vehicle for TCRs from engineered iPSCs

- Harnessing small molecule enhanced, engineered iPSCs to create master cell lines for scalable, off-the-shelf cellular immunotherapies
- Discovering which attributes best enhance TCR function to produce tumorinfiltrating cells with durable responses in vivo whilst minimizing toxicity and GvHD
- Presenting preclinical data on engineered iPSCs for TCR therapy and investigating the best modality for TCR-based therapies

Chia Chen-Rogers
Senior Director,
Oncology Cell
Therapy New
Products
GSK

4.30 Mastermind Session: Planning Ahead: A Commercial Future for Safe & Efficacious TCR-based Therapy Products

- Navigating regulations: What data must be shown for clinical progress? Designing clinical trials to show clear survival advantages. Do the regulatory requirements for TCRs differ from CAR-T frameworks?
- Mastering Value Evidence Generation: Defining the evidence needed to position and support novel product launches and compete in the market. Integrating evidence in pricing & marketing strategies
- Improving Market Access & Patient Care: Discussing the economy of single-treatment high-cost therapies. Contemplating the pros and cons of in-patient vs. out-patient care. Maximizing patient care, from reducing manufacturing time to patient education

5.00 Chair's closing remarks

5.15 Close of Summit

TCR-T holds great promise as the next generation cell therapy for solid tumors. We are excited to be part of the first major gathering focusing on this specific topic

Gang Zeng, Chief Executive Officer,
T-Cure Bioscience Inc.

OUR PARTNERS



Expertise Partner

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing

the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with unprecedented scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

www.adaptivebiotech.com



Expertise Partner

Codex is building biology. Creators of the BioXp™ system, the world's only fully automated

gene synthesis platform, and the industry-standard Gibson Assembly® methodology, Codex empowers researchers with the tools they need to rapidly and securely design, code, and synthesize DNA. Codex is accelerating advances in the fields of personalized medicine, antibody engineering, vaccine development, drug discovery, and DNA data storage.

www.codexdna.com



Miltenyi Biotec

Exhibition Partner

www.miltenyibiotec.com



IMMUNOLOGY TAKEN TO A HIGHER LEVEL

Exhibition Partner

www.immudex.com

■ Hanson Wade's CAR-TCR summit has been already the leading specialized conference in the field – what a great suggestion to set up a dedicated forum for the rapidly growing TCR-T area ■

Steffen Walter, Chief Scientific Officer, Immatics US

COMPANIES ATTENDING INCLUDE

abbvie

BIONTECH



elevatebio



PARTNER WITH US

The TCR-based Therapies Summit is the first and only industry focused, end-to-end meeting dedicated to delivering safe, effective and commercially successful TCR cell therapies.

Bringing together VPs, Directors and C-Level executives searching for support, this is your opportunity to meet with key decision makers and ensure they choose you!

“A great week to connect with current clients, to talk to potential new clients and to hear what the field as a whole is considering as opportunities to pursue”

Key Biologics



Showcase your expertise and educate the industry on how you can support and streamline their efforts



Build new relationships via targeted networking with senior level decision makers from leading pharma and biotech organisations




Drive your brand and cement your reputation to maximize exposure and differentiate yourself from competitors



Educate key decision makers on how your expertise and support can help ensure these therapies achieve their full potential and reach patients in need

ATTENDEES BY SECTOR*

*Based on similar events



Pharma & Biotech Drug Developers

Academic Institutions

Solution Providers

“Everybody at Hanson Wade took ownership in making the event successful; I can clearly see that and appreciate your efforts”

GenScript

GET INVOLVED



Jonathan Kilby-Philips
Commercial Director

Tel: +1 617 455 4188

Email: sponsor@hansonwade.com

DIGITAL EVENTS: AN INTERACTIVE ONLINE EXPERIENCE

The **TCR-based Therapies Summit** is committed to delivering high-quality insights and industry connections, in a format that is accessible from the comfort of your home or office.

We have created the virtual summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

Key Features & Functionalities:



Delegate Profile

Set up personalized profiles to easily identify the name, job title & company of other attendees



Stage Area

Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite



Sessions Area

Smaller groups can get together in this breakout area for panel discussions and other interactive sessions



Demo Area

Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer



Chat Rooms

Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms



Speed Networking

This virtual networking session will connect you with other attendees to establish new industry contacts

What You Can Expect from a Digital Event:



Live Q&As with Speakers

Ask your burning questions directly to our expert speakers in real-time, just as you would at a physical conference



Scientific Poster Session

Peruse the online poster session with the opportunity to ask your questions direct to the researchers. Why not use this session to showcase your own work in front of the leading TCR experts?



7+ Hours of Networking

Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions



Content Available Post-Event

On conclusion of the event, presentations will be made available to attendees where possible

If you have any other questions about the platform, please email info@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

 [www.tcr-therapies-summit.com/
take-part/register/](http://www.tcr-therapies-summit.com/take-part/register/)

 Tel: +1 617 455 4188

 Email: register@hansonwade.com

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Industry Pricing **	Register and Pay by July 31 2020 Save \$300	Standard Pricing
Conference + 2 Workshops (A & B)	\$3097	\$3397
Conference + 1 Workshop (A or B)	\$2498	\$2798
Conference Only	\$1899	\$2199
Workshops (Individual)	\$599	
Standard Pricing	Register and Pay by July 31 2020 Save \$300	Standard Pricing
Conference + 2 Workshops (A & B)	\$3997	\$4297
Conference + 1 Workshop (A or B)	\$3298	\$3598
Conference Only	\$2599	\$2899
Workshops (Individual)	\$699	
Academic Pricing	Register and Pay by July 31 2020 Save \$300	Standard Pricing
Conference + 2 Workshops (A & B)	\$2197	\$2497
Conference + 1 Workshop (A or B)	\$1698	\$1998
Conference Only	\$1199	\$1499
Workshops (Individual)	\$499	

** Must be from a biotech or pharma company that is currently and publicly developing an in-house TCR therapy to be eligible for this price.

■ The TCR-based Therapies Summit will be a great forum to learn from and network with leading scientists and companies working to develop T cells as immunotherapy especially for solid tumors ■

Laurence Cooper, Chief Executive Officer, **Ziopharm Oncology**

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities, tag, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1V 0TH

Code: 17584